HRTX Q4 2023 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+14.0% YoY

Gross Profit

$24M71.1% margin

Operating Income

-$10M-29.9% margin

Net Income

-$11M-31.3% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+8.9%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$2M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$223M

Total Liabilities

$256M

Stockholders' Equity

-$34M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$30M	+14.0%
Gross Profit	$24M	$17M	+39.9%
Operating Income	-$10M	-$20M	+49.8%
Net Income	-$11M	-$20M	+46.0%

Revenue Segments

C I N V A N T I

$48M73%

Z Y N R E L E F

$10M16%

S U S T O L

$7M11%